pharmaceutical investing Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder
pharmaceutical investing Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU
Brixton Metals Announces Upsize of Previously Announced Non-Brokered Private Placement to $8 Million and Closing of Second Tranche
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
